Aldevron’s Post

With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/gNeZZ-Pk

We will be closed on July 4th and 5th to celebrate and observe Independence Day. Everyone at Aldevron wishes you a safe and fun holiday!

Overcoming manufacturing challenges will be essential for large-scale use of mRNA therapies. A recent paper demonstrates how Codex® HiCap RNA Polymerase enables efficient co-transcriptional capping with reduced dsRNA byproducts. This enzyme is now available exclusively through Aldevron contact us to see how it can enhance IVT in your program. https://lnkd.in/gdBs7nc7

ICYMI When dealing with gene editing, delivery technologies are critical to success. As Max Sellman shares from the 2024 ASGCT annual meeting, lipid nanoparticles (LNP) are becoming more widely used as a non-viral delivery technology for #mRNA, with some new breakthroughs emphasizing their potential. https://lnkd.in/grE59wdG

“Our interns don’t just participate in the science, they learn how a high performing workplace culture operates from the inside and how to be part of a team,” said Tom Foti, Vice President and General Manager of Aldevron's Protein Business Unit. We enjoyed sharing a bit about our internship program here at Aldevron as a part of a feature story about our highly accomplished former intern, Nithesh Chandrasekharan, in this University of Wisconsin-Madison article: https://lnkd.in/g8SmAJt9. Nithesh, who was part of Aldevron’s 2023 cohort of graduate student interns, is pursuing a Ph.D. through the Integrated Program in Biochemistry (IPiB) at the University of Wisconsin-Madison. During the internship, Nithesh and the other interns actively participated in hands-on #biotech work at our Madison campus. “One of the biggest reasons I wanted to do an industry internship was that I wanted to see how bench science connects to the business and managerial side of biotech,” said Nithesh. We look forward to witnessing Nithesh and our other interns build strong careers in the industry! #AdvancingEveryDay

We’re excited to see that the FDA has expanded the approval of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), for nearly all patients. Congrats to Sarepta Therapeutics – this approval marks a significant milestone for patients with #DMD, a genetic disorder characterized by progressive muscle loss. We are proud to work with you!    At Aldevron, we envision a world where every cure is possible, and yesterday was a great day! We look forward to witnessing and supporting continued advancements in treatments and cures for patients living with rare and more common diseases. 

“Smaller, safer plasmid DNA backbones are expanding the toolkit for CAR-T developers, helping them reach their goal of bringing life-saving cell therapies to a broader population of cancer patients.” CAR-T therapy holds tremendous promise, but its development also involves many complexities. As we strive to usher in more CAR-T innovations that will bring new cures and treatment for patients, plasmid DNA will play a critical role. Venkata Shravan K Indurthi, Chief Scientific Officer here at Aldevron, recently wrote about the importance of #plasmidDNA in CAR-T therapy development in @BioCompare here: https://lnkd.in/gwdpj_XP #CART #plasmid

On #WorldSickleCellDay, it's important to recognize the millions of individuals worldwide impacted by this inherited blood disorder and emphasize the continued need to drive forward #research and #treatment innovations.   To learn more about sickle cell disorder on this awareness day, check out our blog post featuring Aldevron’s Tom Foti and James Griffin, a sickle cell patient and author of the book "Breaking Silence: Living With Sickle Cell Anemia," who share meaningful insights on the patient perspective.   “It's an exciting time, because so many scientists and companies want to help people with sickle cell,” said James. “I grew up in the 90s, and there was nothing about sickle cell. Now we have technology that may cure sickle cell. Seeing how much we're progressing now gives me so much hope.”   At Aldevron, we work with biotech and pharma companies, as well as academic institutions, to provide custom development and manufacturing services that enable groundbreaking research for sickle cell therapies worldwide. https://lnkd.in/guAr72ch  

Did you know there are more than 800 ongoing clinical trials using CAR-T technology in the United States alone? This means new treatments and cures could be on the horizon for millions of patients.   And all of this could come faster due to recent innovations through plasmid DNA that are improving the efficiency of CAR-T development and manufacturing and providing increased safety profiles of end products.   Aldevron is proud to be a leader in #plasmidDNA, with a team of experts ready to support our clients as they move new therapies from the research stage to final products. Read more from Venkata Shravan K Indurthi on the promise of plasmid DNA in a recent publication from @European Pharmaceutical Manufacturing (page 8)! https://lnkd.in/gfZyaJwB